Tweets
Survey of 686 physicians (Internists, Cardiology, Endo) shows 72% report financial tie to industry. Most common free drug samples (55%), food/beverage (48%), consulting (4%), or scientific advisory board (3%). https://t.co/qV5zAfXaBo
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
The RheumNow Week in Review - Heart Attack Report is up! View here https://t.co/iWogM0X4Mj or listen on iTunes or Soundcloud - podcasting is in! https://t.co/NV62AKnmqz
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Congratulations to the Northwestern University Professor John Varga for receiving the Lifetime Achievement Award from the Scleroderma Foundation
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Oct 31st Sandoz announced that the FDA has approved its adalimumab biosimilar named Hyrimoz (adalimumab-adaz) with indications for RA, JIA, PsA, AS, Crohns, ulcerative colitis and plaque psoriasis. https://t.co/9gH3X51GQj
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
DEA report says 2017 was a record year for Opioid Overdose deaths - 72,000 or ~ 200 deaths per day; lead by Heroin, fentanyl, other opioids, methamphetamine and cocaine. https://t.co/jfayrQbt5d
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Big news? Presented at #ACR18 as an abstract (L10) - small study of 29 primary Sjogrens syndrome pts - 8 Placebo vs 21 on Leflunomide + HCQ. At 24 weeks 1/9 PBO and 9/21 LEF/HCQ responded w/ ESSDAI improved > 3. Surprising, small, needs repeating https://t.co/xC4rA1JFIb
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Here are online abstracts from the Sept 2018 Brazilian Congress of Rheumatology meeting. https://t.co/icB0emM1dN
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
CBC: neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are significantly elevated in #RA and is as effective as CRP & ESR in correlating w/ DAS28-ESR https://t.co/K15vSHywfI https://t.co/xvqMWMqU0t
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Nationwide Inpatient Database (2005-2014) studied 2036 SLE patients with MI (STEMI and NonSTEMI) and showed hospital outcomes (Mortality, CABG, AE, hosp stay, costs) same as non-SLE patients. https://t.co/VpOrNh1fq0
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
In contrast to RF, ACPA is not increased in HCV infection; among 271 HCV‐infected pts (no arthritis) they found 47% RF+, 1.1% ACPA+, 8.9% high‐positive RF, and 1.1% high‐positive ACPA. https://t.co/35wFgGVWcH
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Taiwan claims data shows that among 4036 psoriasis pts with HTN followed for 5.4 yrs, there was a 28% higher risk of cardiovascular procedures and surgery (aHR 1.28; 95% CI, 1.07-1.53); moreso in PsA and with severe psoriasis. https://t.co/cgpY8s3WDs
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Always be student who becomes a teacher
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
The ACR 2018 RheumNow Review is up! Watch it here https://t.co/jtAySYbpKR or listen on iTunes or SoundCloud https://t.co/BBcghpaLEP
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
European Commission (EC) has approved a label update for Cosentyx (secukinumab), now allowing up to 300 mg dosing and also includes 24-week Xray data with inhibition of progression of joint damage in PsA https://t.co/S6d4XE75Ov
Links:
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
